Peter Attia MD#30 – Thomas Seyfried, Ph.D.: Controversial discussion—cancer as a mitochondrial metabolic disease?
CHAPTERS
- 0:04 – 9:04
Episode Preview and Guest Introduction
Peter Attia introduces Tom Seyfried, his background, and the topics ahead, including the Warburg effect, glutamine and the question of whether cancer is metabolic or genetic. He says he does not share all of Tom's views and flags the biopsy disagreement.
- •Seyfried's background in genetics and biochemistry, Yale neurology and Boston College
- •Attia notes he doesn't fully share Seyfried's views and wants to represent the debate
- •Listeners are told to pause and look up respiration versus fermentation
- •Glioblastoma is highlighted as a key model for metabolic therapy
- •Attia is bullish on metabolic, immuno- and chemotherapy together
- 9:04 – 19:09
From Epilepsy and Gangliosides to Cancer Research
Seyfried describes how work on gangliosides, brain tumors and epilepsy at Yale led to ketogenic diet studies. A drug study in mice showed tumor shrinkage that turned out to be due to calorie restriction, not the drug.
- •Early work on ganglioside patterns in human and mouse brain tumors
- •A rejected Yale grant on ketogenic diets around 1980
- •A drug shrank tumors but body weight fell too; weight-matched controls had identical tumor size
- •Ketogenic diets in children work partly through restricted calories
- 19:09 – 31:46
Calorie Restriction, Ketosis, Fasting and Starvation
The conversation covers how calorie restriction and ketosis relate to seizure control, and where therapeutic fasting ends and starvation begins. Seyfried draws on George Cahill's data from hunger-striking prisoners and very long fasts.
- •Equivalent calorie restriction without a ketogenic diet gave the same seizure benefit
- •Mouse restriction of 35–40% compares to water-only fasting in humans
- •Blood sugar spikes can trigger breakthrough seizures in children
- •Starvation begins when muscle breakdown starts; Cahill's data from Irish prisoners
- •Long fasts in obese patients and durability of weight loss
- 31:46 – 42:09
The Warburg Effect and Defective Respiration
Seyfried explains Warburg's observation that cancer cells ferment even in oxygen, and Attia clarifies glycolysis, lactate and mitochondrial respiration. Seyfried argues respiration is damaged in all cancers, citing Pete Peterson's work, and that cell culture misleads.
- •Pasteur effect versus Warburg's finding of lactate production in 100% oxygen
- •Warburg's Nobel was for cytochrome c oxidase, not cancer work
- •Peterson found defects in mitochondrial number, structure or function in every cancer
- •Seyfried says cell-culture oxygen measurements misled the field
- 42:09 – 49:55
Genes, Mitochondria, Viruses and Cancer Origins
They discuss whether cancer arises from germline or somatic mutations versus mitochondrial damage. Seyfried argues inherited mutations are not fully penetrant, that viruses and carcinogens damage mitochondria, and that no non-fermenting cancer has been found.
- •Germline cancers estimated at about five to six percent
- •Seyfried's group found no pathogenic mutations in five mouse tumors
- •Prevention is framed as keeping mitochondria healthy
- •Dean Burk's slow-growing hepatoma work and plant crown gall tumors
- •Plant tumors don't metastasize because they lack an immune system
- 49:55 – 56:39
Building Blocks, Glutamine and Substrate-Level Phosphorylation
Attia raises the biosynthesis explanation for the Warburg effect. Seyfried responds that energy is the missing piece and proposes that mitochondrial substrate-level phosphorylation fueled by glutamine supplies cancer ATP, with cardiolipin defects as supporting evidence.
- •Glucose and glutamine supply carbon and nitrogen building blocks
- •Substrate-level phosphorylation explained, including succinyl-CoA
- •Seyfried says mitochondrial SLP replaces lost oxidative phosphorylation
- •Hochachka's diving-animal experiments cited as SLP precedent
- •Cardiolipin is defective in every tumor the lab has examined
- 56:39 – 1:04:11
Why the Field Disagrees: Oxygen Uptake and Uncoupling
Attia asks why Seyfried's view is a minority one. Seyfried points to the dominance of molecular biologists and the use of instruments like Seahorse, and they debate how to separate coupled from uncoupled oxygen use.
- •Seyfried attributes the minority status to the field's molecular biology orientation
- •Attia rejects conspiracy explanations
- •Warburg said tumor oxygen uptake can be uncoupled from ATP production
- •Mass-balancing ATP is hard because mitochondrial SLP can't be easily separated
- 1:04:11 – 1:18:54
Starving Tumors: Glucose Limits, Ketones, Insulin and Glutamine
They discuss how far glucose can be lowered, how normal cells shift to ketones while tumor cells cannot, and Attia's own insulin suppression test. Seyfried explains the press-pulse concept of pressing glucose and pulsing glutamine with drugs like DON.
- •Glucose can't reach zero but can go very low; normal cells upregulate glucose transporters
- •Attia recounts his near-hypoglycemic insulin suppression test at Stanford
- •Insulin is pro-tumorigenic only when glucose is high, per Seyfried
- •Glutamine can only be lowered with drugs such as DON, not diet
- •Press-pulse protects the immune system and gut
- 1:18:54 – 1:33:41
Testing the Hypothesis: Structure, Function and Cell Types
Attia pushes on whether structural abnormalities necessarily mean functional failure. They discuss why heart and neurons rarely form cancer, why some cells can shift to fermentation, and the role of oncogenes as transcription factors.
- •Attia asks for experiments that could resolve the debate and challenges structure-implies-function
- •Seyfried says cells that can't upregulate fermentation die rather than become tumors
- •Gliomas arise from glial cells, not neurons
- •Oncogenes are described as upregulating glucose and glutamine transport
- •ROS from damaged mitochondria drive nuclear mutations
- 1:33:41 – 1:39:37
Lactate Transport, Avastin and the Tumor Microenvironment
They discuss lactate clearance via the Cori cycle and upregulated MCT transporters. Seyfried then criticizes anti-angiogenic therapy such as Avastin, arguing it drives invasion in brain cancer.
- •Lactic acidosis reported in some leukemias, with Attia offering an alternative explanation
- •MCT transporters carry both lactate and ketones
- •Cancer cells ferment and don't need blood vessels
- •Seyfried calls Avastin ineffective for glioblastoma and says it spreads tumor cells
- •Imaging can look better while survival is unchanged
- 1:39:37 – 1:49:17
Macrophage Fusion and the Origin of Metastasis
Seyfried presents his hypothesis that metastatic cells arise from fusion of macrophages with neoplastic cells, driven by a wound-healing response to lactate. Attia probes how this would cause metastasis and why macrophages do not simply clear the cells.
- •Historical and recent work on macrophage fusion hybrids in melanoma and colon
- •Lactate acts as a fire alarm drawing immune cells
- •Growth factors from healing cells stimulate the neoplastic cells
- •Some metastatic cells show no mutations
- •Timing of metastasis is unpredictable
- 1:49:17 – 2:00:30
Biopsy Disagreement and Extracranial GBM Metastasis
Seyfried suggests needle biopsies may promote spread through inflammatory oncotaxis, and Attia objects strongly that evidence supports only needle-tract seeding. They also discuss extracranial metastasis of glioblastoma found at autopsy.
- •Seyfried cites inflammatory oncotaxis and morcellation as concerns
- •Attia stresses he doesn't want patients refusing biopsies
- •Seyfried admits the controlled experiment hasn't been done
- •Biopsy still informs treatment such as receptor status, per Attia
- •Seyfried says over 100 articles document GBM metastasis outside the brain
- 2:00:30 – 2:11:26
Cancer Mortality and the Dream Clinical Trial
Seyfried argues cancer deaths show the disease is misunderstood and that he expects a 50% drop in mortality in ten years, which Attia challenges using age-adjusted data. Attia asks for the ideal trial, and Seyfried describes a design including a metabolic-therapy-alone arm.
- •Seyfried cites 1,600 US cancer deaths a day
- •Attia questions population-based reasoning and notes about a 3% mortality decline in 50 years
- •Existing studies compare standard care with standard care plus metabolic therapy, missing a metabolic-only arm
- •Press-pulse components: ketosis, glucose-ketone index near 1.0, stress management, insulin, hyperbaric oxygen, glutamine drugs
- 2:11:26 – 2:18:12
Metabolic Therapy in Practice: Protocol, Surgery and Radiation
Seyfried details the therapy's mechanics: ketones favor normal cells, hyperbaric oxygen replaces radiation, and surgery comes after tumor shrinkage. He describes the Turkey work and the Egyptian GBM patient, arguing radiation causes harm.
- •Ketones don't kill cancer cells but fuel normal cells that tumor cells cannot use
- •Hyperbaric oxygen at 2.5 atmospheres for 90 minutes daily
- •Surgery at a midpoint after the tumor is smaller and better demarcated
- •The Turkey group uses low-dose chemo but no glutamine targeting
- •Egyptian patient survived 30 months but died of radiation necrosis, per Seyfried
- 2:18:12 – 2:25:56
Cure Potential, GBM Cases and Clinical Trial Obstacles
Attia asks whether metabolic therapy could cure rather than extend life and why GBM is the ideal test. Seyfried describes unpublished and anecdotal long survivors, and they discuss IRB resistance and how to get trials done.
- •Attia says a 50% mortality cut would require cure, not lead-time effects
- •Mass effect limits delay of surgery, steroids and radiation
- •Seyfried cites a patient alive at four years who refused radiation and chemo; the case is unpublished
- •IRBs would allow metabolic therapy only after standard care failed
- •Attia advises building patient-family pull and a pragmatic compromise of immediate surgery
- 2:25:56 – 2:35:48
Experiments on Mitochondrial Function and Scientific Disagreement
Attia asks for an unambiguous experiment on whether fermentation is merely compensatory. Seyfried points to ketone-only culture and cardiolipin evidence, and accuses the field of ignoring evidence, while Attia seeks collaborative experiments.
- •Seyfried says cells survive on ketones only if mitochondria work, and cancer cells die
- •Accuses reviewers and journals of ignoring Peterson's evidence
- •Compares the situation to geocentrism; Attia pushes back on the analogy
- •Attia sees a stalemate and wants jointly designed experiments
- 2:35:48 – 2:48:20
Advice, Funding and Closing Thoughts
Attia urges Seyfried to build patient advocacy and to see metabolic oncology as one more branch of oncology rather than a fight over genetic versus metabolic disease. Seyfried explains how to fund his lab, and they close on risk in trials.
- •Attia advises pull via family advocates, like the Charlie Foundation in epilepsy
- •Attia argues cancer is a very hard disease needing every therapy, including metabolic oncology
- •Seyfried names the Metabolic Therapy Foundation and Boston College as routes for donations
- •Attia notes there is some risk and that claiming none harms credibility
